Plasma lipopolysaccharide binding protein and bactericidal/permeability increasing factor in CRF and HD patients

Journal of the American Society of Nephrology

Volumn 7, Issue 3, 1996, Pages 479-487

  Pereira, Brian J G ^a   Sundaram, Sumuk ^a   Snodgrass, Brad ^a   Hogan, Pamela ^a   King, Andrew J ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Bactericidal permeability increasing factor; Cytokines; Hemodialysis; Lipopolysaccharide binding protein

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LIPOPOLYSACCHARIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY;

EID: 0029870092     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v73479     Document Type: Article

References (51)

1. Himmelfarb J, Hakim RM: Biocompatibility and risk of infection in hemodialysis patients. Nephrol Dial Transplant 1994;9:138-144.
2. Ruiz P, Gomez F, Schreiber AD: Impaired function of macrophage Fc receptors in end-stage renal disease. N Engl J Med 1990;322:717-722.
3. Goldblum SE, Reed WP: Host defenses and immunologic alterations associated with chronic hemodialysis. Ann Intern Med 1980;93:597-613.
4. Vanholder R, Ringoir S: Infectious morbidity and defects of phagocytic function in end-stage renal disease: A review. J Am Soc Nephrol 1993;3:1541-1554.
5. Vanherweghem J-L, Tielemans C, Goldman M, Boelaert J: Infections in chronic hemodialysis patients. Semin Dial 1991;4:240-244.
6. Dinarello CA: The role of interleukin-1 in disease. N Engl J Med 1993;328:106-113.
7. Beutler B, Cerami A: Cachectin: More than a tumor necrosis factor. N Engl J Med 1987;316:379-385.
8. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE: Endotoxemia in human septic shock. Chest 1991;99:169-175.
9. Pabst MJ, Hedegaard HB, Johnston RB, Jr: Cultured human monocytes require exposure to bacterial products to maintain an optimal oxygen radical response. J Immunol 1982;128:123-128.
10. Ding AH, Nathan CF: Trace levels of bacterial lipopolysaccharide prevent interferon-gamma or tumor necrosis factor-alpha from enhancing mouse peritoneal macrophage respiratory burst capacity. J Immunol 1987;139: 1971-1977.
11. Ding AH, Sanchez E, Srimal S, Nathan CF: Macrophages rapidly internalize their tumor necrosis factor receptors in response to bacterial lipopolysaccharide. J Biol Chem 1989;164:3924-3929.
12. Blanchard DK, Djeu JY, Klein TW, Friedman H, Stewart WE II: Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leukocyte Biol 1988; 43:429-435.
13. Moldawer LL: Interleukin-1, TNFα and their naturally occurring antagonists in sepsis. Blood Purif 1993;11: 128-133.
14. Tracey KJ, Beutler B, Lowry SF, et al.: Shock and tissue injury induced by recombinant human cachectin. Science (Washington DC) 1986;234:470-474.
15. Tobias PS, Soldau K, Ulevitch FJ: Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem 1989;264:10867-10871.
16. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD 14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science (Washington DC) 1990;249:1431-1433.
17. Mathison JC, Wolfson E, Steinemann S, Tobias PS, Ulevitch RJ: Lipopolysaccharide (LPS) recognition in macrophages. Participation of LPS-binding protein and CD 14 in LPS-induced adaptation in rabbit peritoneal exudate macrophages. J Clin Invest 1993;92:2053-2059.
18. Pereira HA, Spitznagel JK, Winton EF, et al.: The ontogeny of a 57-Kd cationic antimicrobial protein of human polymorphonuclear leukocytes: localization to a novel granule population. Blood 1990;76:825-834.
19. Marra MN, Wilde CG, Griffith JE, Snable JL, Scott RW: Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol 1990;144:662-666.
20. Marra MN, Wilde CG, Collins MS, Snable JL, Thornton MB, Scott RW: The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 1992;148:532-537.
21. Schumann RR, Leong SR, Flagg GW, et al.: Structure and function of lipopolysaccharide binding protein. Science (Washington DC) 1990;249:1429-1431.
22. Gray PW, Flaggs G, Leong SR, et al.: Cloning of the cDNA of a human neutrophil bactericidal protein. J Biol Chem 1989;264:9595-9599.
23. Hoess A, Watson S, Siber G, Liddington R: Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, limulus-anti-LPS factor, at 1.5 A resolution. EMBO (Eur Mol Biol Org) J 1993;12:3351-3556.
24. 233, a fragment of bactericidal/ permeability-increasing protein and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect Immun 1994;62:1185-1191.
25. Wilde CG, Seilhamer JJ, McGrogan MP, et al.: Bactericidal/permeability-increasing protein and lipopolysaccharide (LPS)-binding protein: LPS binding properties and effects on LPS mediated cell activation. J Biol Chem 1994;26:17411-17416.
26. Lonnemann G, Mahiout A, Schindler R, Colton CK: Pyrogen retention by the polyamide membranes. In: Shaldon S, Koch KM, Eds. Contributions in Nephrology. Polyamide - The Evolution of a Synthetic Membrane for Renal Therapy. 1992;96:47-63.
27. Poutsiaka DD, Clark BD, Vannier E, Dinarello CA: Production of interleukin-1 receptor antagonist and interleukin-1β by peripheral blood mononuclear cells is differentially regulated. Blood 1991;78:1275-1281.
28. Pereira BJG, Poutsiaka DD, Strom JA, et al.: In vitro production of interleukin-1 receptor antagonist in chronic renal failure, CAPD and HD. Kidney Int 1992; 42:1419-1424.
29. Pereira BJG, King AJ, Falagas ME, Dinarello CA: Interleukin-1 receptor antagonist (IL-1Ra) and index of dialysis-induced interleukin-1 production. Nephron 1994; 67:358-361.
30. Pereira BJG, Snodgrass B, King AJ, Hogan P: Diffusive and convective transfer of cytokine-inducing bacterial products across hemodialysis membranes. Kidney Int 1995;47:603-610.
31. Lonnemann G, Endres S, van der Meer JW, Cannon JG, Dinarello CA: A radioimmunoassay for human interleukin-1 alpha: measurement of IL-1 alpha produced in vitro by human blood mononuclear cells stimulated with endotoxin. Lymphokine Res 1988;7:75-84.
32. Mathison JC, Tobias PS, Wolfson E, Ulevitch RJ: Plasma lipopolysaccharide (LPS)-binding protein. A key component in macrophage recognition of gram-negative LPS. J Immunol 1992;149:200-206.
33. Dentener MA, Asmuth EJU, Francot GJM, Marra MN, Buurman WA: Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability increasing factor on lipopolysaccharide-induced cytokine release by mononuclear cells. J Immunol 1993;151:4258-4265.
34. Calvano SE, Thompson WA, Marra MN, et al.: Changes in polymorphonuclear leukocyte surface and plasma bacterial/permeability increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis. Arch Surg 1994;129:220-226.
35. Opal SM, Papardy JE, Marra MN, Fisher CJ Jr, McKelligon BM, Scott RW: Relative concentrations of endotoxin-binding proteins in body fluids during infection. Lancet 1994;344:429-431.
36. Honkanen E, Gronhagen-Riska C, Teppo AM, Maury CPJ, Meri S: Acute-phase proteins during hemodialysis: Correlations with serum interleukin-1β levels and different membranes. Nephron 1991;57:283-287.
37. Docci D, Bilancioni R, Baldrati L, Capponcini C, Turci F, Feletti C: Elevated acute phase reactants in hemodialysis patients. Clin Nephrol 1990;34:88-91.
38. Haubitz M, Schulze M, Koch KM: Increase of C-reactive protein serum values following hemodialysis. Nephrol Dial Transplant 1990;5:500-503.
39. Schindler R, Marra MN, McKelligon BM, et al.: Plasma levels of bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide binding protein (LBP) during hemodialysis. Clin Nephrol 1993;40:346-351.
40. Rogy MA, Oldenburg HSA, Calvano SE, et al.: The role of bacterial/permeability increasing protein in the treatment of primate bacteremia and septic shock. J Clin Immunol 1994;14:120-133.
41. Fisher CJ, Opal SM, Scott R, Marra M, Palardy JE: Bactericidal/permeability-increasing protein as a novel anti-endotoxin treatment modality in septic shock. Crit Care Med 1994;22:553-558.
42. Wright SD, Ramos RA, Patel M, Miller DS: Septin: A factor in plasma that opsonizes lipopolysaccharide-bearing particles for recognition by CD14 on phagocytes. J Exp Med 1992;176:719-727.
43. Bazil V, Horejsi V, Baudys M, et al.: Biochemical characterization of a soluble form of the 53-kDa monocyte surface antigen. Eur J Immunol 1986;16:1583-1589.
44. Schutt C, Schilling T, Grunwald U, Schonfeld W, Kruger C: Endotoxin-neutralizing capacity of soluble CD14. Res Immunol 1992;143:71-78.
45. Lonnemann G, Binge M, Floege J, Koch KM, Shaldon S, Dinarello CA: Detection of endotoxin-like interleukin-1-inducing activity during in vitro dialysis. Kidney Int 1988;33:29-35.
46. Evans RC, Holmes CJ: In vitro study of the transfer of cytokine-inducing substances across selected high-flux hemodialysis membranes. Blood Purif 1991;9:92-101.
47. Lonnemann G, Behme TC, Lenzner B, et al.: Permeability of dialyzer membranes to TNFα-inducing substances derived from water bacteria. Kidney Int 1992;42:61-68.
48. Henderson LW, Koch KM, Dinarello CA, Shaldon S: Hemodialysis hypotension: The interleukin-1 hypothesis. Blood Purif 1983;1:3-8.
49. Dinarello CA: Cytokines: Agents provocateurs in hemodialysis. Kidney Int 1992;41:683-694.
50. Pereira BJG, Dinarello CA: Production of pro-inflammatory cytokines and cytokine inhibitory proteins in patients on dialysis. Nephrol Dial Transplant 1994;9:60-71.
51. Schindler R, Lonnemann G, Shaldon S, Koch KM, Dinarello CA: Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement. Kidney Int 1990;37:85-93.